Skip to content

IMMUNOBLUE, LLC

BETHESDA, MD

Oncologycell therapyGrant-only

What changed

NIH R01 · $0.2M · Photothermal Nanoparticles Immune Engineer Tumor-specific T cells for Adoptive Cell Therapy

5mo agoGrant renewalJan 23, 2026Source filing (opens the source filing in a new tab)

Momentum

40no change

Momentum 40 out of 100, unchanged since the last recompute.

Some recent activity, at a steady rate.

Runway (estimate)

unknown

No disclosed raise on file, so there is nothing to model from.

Stage

Grant-only

The furthest-along thing in the public record. Not a projection.

Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.

Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources